


MMP-9/MMP-13 Inhibitor I

Cat. No.:	HY-128026		
CAS No.:	204140-01-2		
Molecular Formula:	C ₂₅ H ₂₅ N ₃ O ₆ S		
Molecular Weight:	495.55		
Target:	MMP		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (504.49 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
			1 mM	2.0180 mL	10.0898 mL	20.1796 mL
			5 mM	0.4036 mL	2.0180 mL	4.0359 mL
			10 mM	0.2018 mL	1.0090 mL	2.0180 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.20 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.20 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.20 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	MMP-9/MMP-13 Inhibitor I is a potent MMP-9 and MMP-13 inhibitor with IC ₅₀ s of both 0.9 nM. MMP-9/MMP-13 Inhibitor I shows >20-folds selectivity for MMP-9/MMP-13 over other MMPs ^[1] .			
IC ₅₀ & Target	MMP-9 0.9 nM (IC ₅₀)	MMP-13 0.9 nM (IC ₅₀)	MMP-1 43 nM (IC ₅₀)	MMP-3 23 nM (IC ₅₀)
	MMP-7 931 nM (IC ₅₀)			

In Vitro

MMP-9/MMP-13 Inhibitor I (compound 35) inhibits MMP-1, MMP-3, and MMP-7 with IC₅₀ values of 43 nM, 23 nM, and 931 nM, respectively^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. M Cheng, et al. Design and synthesis of piperazine-based matrix metalloproteinase inhibitors. J Med Chem. 2000 Feb 10;43(3):369-80.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA